Evaluations of risk factors of uti in patients with type 2 dm taking sglt2 inhibitors

• At: Glasgow (Scotland) (2018)
• Type: Poster
• Poster code: POS-HPS-069
• By: HUANG, Yu-Chen (MacKay Memorial Hospital, Pharmacy)
• Co-author(s): Yu-Chen Huang: Pharmacy, MacKay Memorial Hospital, Hsinchu, Taiwan, Province of China
  Kai-Hsun Lo: Pharmacy, MacKay Memorial Hospital, Hsinchu, Taiwan, Province of China
  Hsiao-Huai Kuo: Pharmacy, MacKay Memorial Hospital, Hsinchu, Taiwan, Province of China
  Yatzu Hu: Pharmacy, MacKay Memorial Hospital, Hsinchu, Taiwan, Province of China
  
• Abstract:

  Background

  Sodium glucose co-transporter-2 (SGLT2) inhibitors decrease blood glucose by increasing urinary glucose excretion, which increases the risk of urinary tract infection (UTI) in patients with type 2 diabetes mellitus (T2DM).

  Methods

  We reviewed medical records of patients who were diagnosed T2DM and used dapagliflozin or empagliflozin in
  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login